1 week Ago By ABMN Staff
Shares of Charles River Laboratories International, Inc. ( NYSE:CRL – Get Free Report ) saw unusually-high trading volume on Friday . Approximately 2,386,364 shares changed hands during mid-day trading, an increase of 191% from the previous session’s volume of 820,287 shares.
The stock last traded at $97.76 and had previously closed at $99.95.
Analyst Upgrades and Downgrades Several equities analysts recently commented on the company. Robert W. Baird dropped their price objective on Charles River Laboratories International from $177.
00 to $173.00 and set a “neutral” rating on the stock in a research note on Thursday, February 20th. UBS Group reiterated a “neutral” rating and set a $185.
00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Mizuho dropped their price objective on shares of Charles River Laboratories International from $175.
00 to $155.00 and set a “neutral” rating for the company in a report on Wednesday. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.
00 target price on the stock in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $175.
00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. One analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the stock.
Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $182.00. Check Out Our Latest Stock Analysis on Charles River Laboratories International Charles River Laboratories International Price Performance Charles River Laboratories International ( NYSE:CRL – Get Free Report ) last issued its quarterly earnings data on Wednesday, February 19th.
The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.
16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million.
Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%.
Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year. During the same period last year, the company posted $2.
46 earnings per share. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.
36 earnings per share for the current fiscal year. Insider Transactions at Charles River Laboratories International In related news, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th.
The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75.
Following the purchase, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This represents a 3.
42 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink . Also, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th.
The shares were bought at an average price of $164.63 per share, with a total value of $249,249.82.
Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.
83 % increase in their position. The disclosure for this purchase can be found here . Insiders own 1.
30% of the company’s stock. Hedge Funds Weigh In On Charles River Laboratories International Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc.
increased its holdings in shares of Charles River Laboratories International by 1.0% during the 4th quarter. Vanguard Group Inc.
now owns 6,158,926 shares of the medical research company’s stock worth $1,136,938,000 after buying an additional 60,497 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Charles River Laboratories International by 9.0% in the 4th quarter.
Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock valued at $752,508,000 after purchasing an additional 335,658 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Charles River Laboratories International by 2.7% in the 4th quarter.
Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Charles River Laboratories International by 1.2% in the 4th quarter.
Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after buying an additional 14,787 shares during the last quarter. Finally, Ariel Investments LLC boosted its position in shares of Charles River Laboratories International by 18.9% in the 4th quarter.
Ariel Investments LLC now owns 1,067,327 shares of the medical research company’s stock valued at $197,029,000 after purchasing an additional 169,640 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.
About Charles River Laboratories International ( Get Free Report ) Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). Further Reading Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.
com's FREE daily email newsletter ..
